Literature DB >> 16103152

Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66.

Erich Hoffmann1, Kutubuddin Mahmood, Zhongying Chen, Chin-Fen Yang, Joshua Spaete, Harry B Greenberg, M Louise Herlocher, Hong Jin, George Kemble.   

Abstract

Cold-adapted (ca) B/Ann Arbor/1/66 is the influenza B virus strain master donor virus for FluMist, a live, attenuated, influenza virus vaccine licensed in 2003 in the United States. Each FluMist vaccine strain contains six gene segments of the master donor virus; these master donor gene segments control the vaccine's replication and attenuation. These gene segments also express characteristic biological traits in model systems. Unlike most virulent wild-type (wt) influenza B viruses, ca B/Ann Arbor/1/66 is temperature sensitive (ts) at 37 degrees C and attenuated (att) in the ferret model. In order to define the minimal genetic components of these phenotypes, the amino acid sequences of the internal genes of ca B/Ann Arbor/1/66 were aligned to those of other influenza B viruses. These analyses revealed eight unique amino acids in three proteins: two in the polymerase subunit PA, two in the M1 matrix protein, and four in the nucleoprotein (NP). Using reverse genetics, these eight wt amino acids were engineered into a plasmid-derived recombinant of ca B/Ann Arbor/1/66, and these changes reverted both the ts and the att phenotypes. A detailed mutational analysis revealed that a combination of two sites in NP (A114 and H410) and one in PA (M431) controlled expression of ts, whereas these same changes plus two additional residues in M1 (Q159 and V183) controlled the att phenotype. Transferring this genetic signature to the divergent wt B/Yamanashi/166/98 strain conferred both the ts and the att phenotypes on the recombinant, demonstrating that this small, complex, genetic signature encoded the essential elements for these traits.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103152      PMCID: PMC1193632          DOI: 10.1128/JVI.79.17.11014-11021.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Restriction of viral replication by mutation of the influenza virus matrix protein.

Authors:  Teresa Liu; Zhiping Ye
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus.

Authors:  A I Klimov; N J Cox; W V Yotov; E Rocha; G I Alexandrova; A P Kendal
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

Review 3.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

4.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60.

Authors:  Hong Jin; Bin Lu; Helen Zhou; Chienhui Ma; Jackie Zhao; Chin-fen Yang; George Kemble; Harry Greenberg
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

5.  Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence.

Authors:  A M Donabedian; D C DeBorde; H F Maassab
Journal:  Microb Pathog       Date:  1987-08       Impact factor: 3.738

Review 6.  Development and characterization of cold-adapted viruses for use as live virus vaccines.

Authors:  H F Maassab; D C DeBorde
Journal:  Vaccine       Date:  1985-12       Impact factor: 3.641

7.  Sequence comparison of wild-type and cold-adapted B/Ann Arbor/1/66 influenza virus genes.

Authors:  D C DeBorde; A M Donabedian; M L Herlocher; C W Naeve; H F Maassab
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

8.  A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence.

Authors:  A M Donabedian; D C DeBorde; S Cook; C W Smitka; H F Maassab
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

9.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.

Authors:  L G Rudenko; A N Slepushkin; A S Monto; A P Kendal; E P Grigorieva; E P Burtseva; A R Rekstin; A L Beljaev; V E Bragina; N Cox
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

10.  Attenuation and phenotypic stability of influenza B/Texas/1/84 cold-adapted reassortant virus: studies in hamsters and chimpanzees.

Authors:  M H Snyder; W T London; H F Maassab; B R Murphy
Journal:  J Infect Dis       Date:  1989-10       Impact factor: 5.226

View more
  23 in total

1.  Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 2.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

3.  Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.

Authors:  Grace L Chen; Ji-Young Min; Elaine W Lamirande; Celia Santos; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Infect Dis       Date:  2011-01-21       Impact factor: 5.226

4.  Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells.

Authors:  Angela Pizzolla; Zhongfang Wang; Joanna R Groom; Katherine Kedzierska; Andrew G Brooks; Patrick C Reading; Linda M Wakim
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 5.  Development of a Universal Influenza Vaccine.

Authors:  Leonardo D Estrada; Stacey Schultz-Cherry
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

6.  Extending the cytoplasmic tail of the influenza a virus M2 protein leads to reduced virus replication in vivo but not in vitro.

Authors:  Wai-Hong Wu; Andrew Pekosz
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

7.  Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Authors:  Victor C Huber; Loren H Kleimeyer; Jonathan A McCullers
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

8.  Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets.

Authors:  Zhongying Chen; Celia Santos; Amy Aspelund; Laura Gillim-Ross; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

9.  H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines.

Authors:  Xing Cheng; Michael Eisenbraun; Qi Xu; Helen Zhou; Deepali Kulkarni; Kanta Subbarao; George Kemble; Hong Jin
Journal:  PLoS One       Date:  2009-02-11       Impact factor: 3.240

Review 10.  Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

Authors:  Christopher S Ambrose; Catherine Luke; Kathleen Coelingh
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.